Prot # ICT-107-201: A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients with Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation

Project: Research project

Project Details

StatusFinished
Effective start/end date7/19/117/19/17

Funding

  • Aptiv Solutions (Prot # ICT-107-201)
  • ImmunoCellular Therapeutics, Ltd. (Prot # ICT-107-201)